Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
The company had recorded a loss of $1.33 per share in the year-ago quarter. Total revenues, comprising license and collaboration revenues, came in at $7.4 million in the first quarter compared with $24.2 million in the year-ago period. The top line missed the Zacks Consensus Estimate of $14 million. Quarter in Detail Research and development expenses amounted to $84.8 million in the first quarter, down almost 14.8% from the year-ago quarter's level. General and administrative expenses totaled $26.7 million, increasing around 14.1% year over year. As of Mar 31, 2024, BEAM had cash, cash equivalents and marketable securities worth $1.1 billion compared with $1.2 billion as of Dec 31, 2023. Shares of BEAM have plunged 17.2% in the year-to-date period compared with the industry's 6.2% decline. Image Source: Zacks Investment Research Pipeline Updates The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, in the phase I/II BEACON study for the tr
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressGlobeNewswire
- Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target lowered by analysts at Barclays PLC from $42.00 to $33.00. They now have an "equal weight" rating on the stock.MarketBeat
- Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
BEAM
Earnings
- 5/7/24 - Beat
BEAM
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/29/24 - Form 4
- BEAM's page on the SEC website